Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-07-04
2006-07-04
Helms, Larry R. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388210, C424S130100, C424S141100, C536S024500, C435S070210
Reexamination Certificate
active
07071311
ABSTRACT:
The present invention relates to antibodies, antibody conjugates, and compositions thereof, methods of antibody synthesis, and applications of antibodies useful for detecting the presence of nucleic acid molecules in vivo, such as in a clinical setting. The antibodies of the invention are also useful as screening agents which allow the selection of candidate therapeutic molecules for optimum bioavailability and/or activity, and as delivery agents for cell and tissue specific delivery of nucleic acid molecules.
REFERENCES:
patent: 4987071 (1991-01-01), Cech et al.
patent: 5028524 (1991-07-01), Fujisawa et al.
patent: 5395938 (1995-03-01), Ramakrishnan
patent: 5589332 (1996-12-01), Shih et al.
patent: 5672695 (1997-09-01), Eckstein et al.
patent: 5741679 (1998-04-01), George et al.
patent: 5767263 (1998-06-01), Usman et al.
patent: 5807718 (1998-09-01), Joyce et al.
patent: 5834186 (1998-11-01), George et al.
patent: 5849902 (1998-12-01), Arrow et al.
patent: 5871914 (1999-02-01), Nathan et al.
patent: 5989912 (1999-11-01), Arrow et al.
patent: 5998203 (1999-12-01), Matulic-Adamic
patent: 6001311 (1999-12-01), Brennan
patent: 6087188 (2000-07-01), Johansen et al.
patent: 6127173 (2000-10-01), Eckstein et al.
patent: 6159714 (2000-12-01), Usman et al.
patent: 6342221 (2002-01-01), Thorpe et al.
patent: WO 93/23569 (1993-11-01), None
patent: WO 96/10390 (1996-04-01), None
patent: WO 96/10391 (1996-04-01), None
patent: WO 96/10392 (1996-04-01), None
patent: WO 97/26270 (1997-07-01), None
patent: WO 98/27104 (1998-06-01), None
patent: WO 98/58058 (1998-12-01), None
patent: WO 99/29842 (1999-06-01), None
patent: WO 99/54459 (1999-10-01), None
patent: WO 99/55857 (1999-11-01), None
patent: WO 00/24931 (2000-05-01), None
patent: WO 00/26226 (2000-05-01), None
Reines D. Analytical Biochemistry, 196(2):367-372, Aug. 1, 1991.
Shefner et al. Journal of Experimental Medicine 173:287-296, Feb. 1991.
Radka et al. Analytical Biochemistry, 307(1):40-46, Aug. 1, 2002.
U.S. Appl. No. 09/800,594, filed Mar. 6, 2001, Usman et al.
U.S. Appl. No. 10/201,394, filed Jul. 22, 2002, Vargeese et al.
U.S. Appl. No. 08/878,640, filed Mar. 6, 2001, Ludwig et al.
U.S. Appl. No. 09/476,387, filed Dec. 30, 1999, Beigelman et al.
U.S. Appl. No. 09/918,728, filed Jul. 31, 2001, Beigelman et al.
U.S. Appl. No. 08/878,640, filed Mar. 6, 2001, Ludwig et al.
Bass, “The short answer,”Nature411:428-429 (2001).
Beigelman et al., “Synthesis of 2′-modified nucleotides and their incorporation into hammerhead ribozymes,”Nucleic Acids Research23(21):4434-4442 (1995).
Bellon et al., “Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes,”Nucleosides&Nucleotides16:951-954 (1997).
Bellon et al., “Post-synthetically Ligated Ribozymes: An Alternative Approach to Iterative Solid Phase Synthesis,”Bioconjugate Chem.8:204-212 (1997).
Breaker et al., “A DNA enzyme with Mg2-dependent RNA phosphoesterase activity,”Chemistry&Biology2(10):655-660 (1995).
Breaker, “Are engineered proteins getting competiton from RNA?”Current Opinion in Biotechnology7:442-448 (1996).
Breaker, “Catalytic DNA: in training and seeking employment,”Nature Biotechnology17:422-423 (1999).
Brennan et al., “Two-Dimensional Parallel Array Technology as a New Approach to Automated Combinatorial Solid-Phase Organic Synthesis,”Biotechnology and Bioengineering(Combinatorial Chemistry) 61:33-45 (1998).
Brody and Gold, “Aptamers as therapeutic and diagnostic agents,”Reviews in Molecular Biotechnology74:5-13 (2000).
Burgin et al., “Chemically Modified Hammerhead Ribozymes with improved Catalytic Rates,”Biochemistry35:14090-14097 (1996) (volume no. mistakenly listed as 6).
Caruthers et al., “Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs,”Methods in Enzymology211:3-19 (1992).
Cech, “Ribozymes and Their Medical Implications,”JAMA260:3030-3034 (1988).
Chartrand et al., “An oligodeoxyribonucleotide that supports catalytic activity in the hammerhead ribozyme domain,”Nucleic Acids Research23(20):4092-4096 (1995).
Crooke et al., “Antisens '97: A roundtable on the state of the idustry,”Nature Biotechnology15:519-524 (1997).
Crooke, “Advances in Understanding the Pharmacological Properties of Antisense Oligonucleotides,”Advances in Pharmacology40:1-49 (1997).
Crooke, “Antisense Therapeutics,”Biotechnology and Genetic Engineering Reviews15:121-157 (1998).
Crooke, “Progress in Antisense Technology: The End of the Beginning,”Methods in Enzymology313:3-45 (1999).
Delihas et al., “Natural antisense RNA/target RNA interactions: Possible models for antisense oligonucleotide drug design,”Nature Biotechnology15:751-753 (1997).
Duval-Valentin, “Specific inhibition of transcription by triple helix-forming oligonucleotides,”Proc. Natl. Acad. Sci. USA89:504-508 (1992).
Egholm et al., “PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules,”Nature365:566-568 (1993).
Elibashir et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells,”Nature411:494-498 (2001).
Fox, “Targeting DNA with Triplexes,”Current Medicinal Chemistry7:17-37 (2000).
Freier et al., “Improved free-energy parameters for predictions of RNA duplex stability,”Proc. Natl. Acad. Sci. USA83:9373-9377 (1986) [sometimes referred to as Frier].
Gold et al., “Diversity of Oligonucleotide Functions,”Annu. Rev. Biochem.64:763-797 (1995).
Halloran and Parker, “The Preparation of Nucleotide-Protein Conjugates: Carbodiimides as Coupling Agents,”Journal of Immunology96:373-378 (1966).
Hammann et al., “Length Variation of Helix III in a Hammerhead Ribozyme and its Influence on Cleavage Activity,”Antisense&Nucleic Acid Drug Development9:25-31 (1999).
Hermnn and Patel, “Adaptive Recognition by Nucleic Acid Aptamers,”Science287:820-825 (2000).
Hertel et al., “Numbering System for the Hammerhead,”Nucleic Acids Research20:3252 (1992).
Ishiwata et al., “Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether,”Chem. Pharm. Bull.43:1005-1011 (1995) (mistakenly referred to as Ishiwataet).
Jayasena, “Aptamers: An Emerging Class of Molecules that Rival Antibodies in Diagnostics,”Clinical Chemistry45:1628-1650 (1999).
Kearney et al., “A New Mouse Myeloma Cell Line That Has Lost Immunoglobulin Expression but Permits the Construction of Antibody-Secreting Hybrid Cell Lines,”Journal of Immunology123:1548-1550 (1979).
Kore, et al., “Sequence specificity of the hammmerhead ribozyme revisistsed; the NIH rule,”Nucleic Acids Research, 26(18):4116-4120 (1998).
Kusser, “Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution,”Reviews in Molecular Biotechnology74:27-38 (2000).
Lasic and Needham “The ‘Stealth’ Liposome: A Prototypical Biomaterial,”Chemical Reviews95:2601-2627 (1995).
Lasic and Papahadjopoulaos, “Liposomes Revisited,”Science267:1275-1276 (1995).
Limbach et al., “Summary: the modified nucleosides of RNA,”Nucleic Acids Research22(12):2183-2196 (1994).
Liu et al., “Cationic Liposome-mediated Intravenous Gene Delivery,”J. Biol. Chem.270(42):24864-24870 (1995).
Moore and Sharp, “Site-Specific Modification of Pre-mRNA: The 2′-Hydroxyl Groups at the Splice Sites,”Science256:992-996 (1992).
Oku et al., “Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography,”Biochimica et Biophysica Acta1238:86-90 (1995).
Player and Torrence, “The 2-5A System: Modulation of Viral and Cellular Processes Through Acc
Beigelman Leonid
Peter Haeberli
Radka Susan
Blanchard David J.
Helms Larry R.
McDonnell Boehnen & Hulbert & Berghoff LLP
Sirna Therapeutics, Inc.
LandOfFree
Antibodies having specificity for 2′-C-allyl nucleic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies having specificity for 2′-C-allyl nucleic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies having specificity for 2′-C-allyl nucleic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3600080